• Skip to primary navigation
  • Skip to main content
ALS Untangled®
  • How to Use
  • Mission & Methods
  • Completed Reviews
  • Future Reviews
  • Search
  • English
    • English
    • Español

Search ALS Untangled®

Pre-clinical models (animal or cell models recognized by ALSUntangled reviewers to be relevant to ALS)

Mototab

January 3, 2012

Given the lack of demonstrated effectiveness, and the above-documented concerns about product safety and supplier identity and reliability, ALSUntangled does not support the use of mototab for amyotrophic lateral sclerosis or any other motor neuron disease. If Oslo Health Solutions ever con-tacts us with additional useful information on this product we will gladly publish an […]

Dean Kraft, Energy Healer

October 10, 2011

In our opinion, Dean Kraft’s energy healing lacks a plausible scientific rationale. The experiments listed on his website as proof of his being able to emit some sort of energy have never been published in a peer-reviewed journal and thus cannot be properly validated. The strongest evidence for his being able to heal ALS comes […]

NuTech Mediworld

May 5, 2011

Now 26 months old, ALSUntangled (www.alsuntangled. org) investigates alternative and off-label treatment options in ALS using social networking tools. Our twitter and NING memberships continue to grow. To date we have published 10 investigations on 11 different alternative and off-label treatment options, collaborating with Quackwatch (www. quackwatch.org), Patients Like Me (www.patients likeme.com) and ALS Worldwide (www.alsworld […]

Luteolin and Lutimax

May 5, 2011

In summary, luteolin is an interesting naturally occurring bioflavinoid that has been shown to have a myriad of functions in various models that could potentially be useful in slowing progression in patients with ALS. However, convincing data to support any positive effect on human ALS do not yet exist. Furthermore, there are legitimate reasons to […]

Low dose naltrexone for ALS

December 21, 2010

Additional pharmacologic studies of LDN are needed to clarify its mechanisms of action. Some of its proposed mechanisms such as immunomodulation and neuroprotection could potentially be useful in ALS. However, there are no convincing data thus far to suggest that this is the case, and some limited data even raise a theoretical potential for a […]

Marty Murray’s Method

September 9, 2010

In our opinion, there are many serious problems with MM’s approach. First, ALSUntangled is aware of no evidence to support MM’s theory on ALS pathogenesis. No case of ALS has ever been shown to be caused or exacerbated by emotional repression. Statements that patients may have somehow caused their own ALS by repressing their emotions […]

The Stowe/Morales ALS Protocol

June 15, 2010

In summary, ALSUntangled strongly recommends that patients with ALS avoid the Stowe/Morales ALS Protocol. The rationale for this exorbitantly expensive protocol is unsound. The specific treatments being used range from mysterious, to already disproven, to potentially harmful. No valid outcome measures are being followed and the discussion of safety and efficacy taking place between sellers […]

The XCell-Center

April 29, 2010

While we applaud the use of informed consent for portions of the XCell-Center protocol, and the presentation of pilot efficacy and safety data, in our opinion many worrisome questions and problems remain. From a rational standpoint, we feel it is unlikely that all the diverse diseases (some without a name at all) being treated at […]

  • « Go to Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Go to Next Page »
© 2025 ALS Untangled® · All rights reserved · Website by Code the Dream & Tomatillo Design
Search ALS Untangled®